Slingshot members are tracking this event:
Allergan Receives Positive Opinion For Truberzi (Eluxadoline) For Treatment Of Irritable Bowel Syndrome With Diarrhoea (IBS-D) In Adults
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
-- Significant step towards bringing the only licensed prescription medication for IBS-D to patients in 28 countries of the European Union(2-4) --
-- Further demonstrates Allergan's commitment to addressing unmet medical needs in gastrointestinal disease by providing innovative medicines for patients and physicians --
TRUBERZI® significantly reduced two of the most bothersome symptoms of IBS-D, abdominal pain and diarrhoea, with sustained relief demonstrated over six months1,2. TRUBERZI® was generally well tolerated with the most common side effects being nausea, constipation, and abdominal pain1,2.
Slingshot Insights Explained
Jul 25, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Truberzi, Eluxadoline, Irritable Bowel Syndrome, Ibs-d, Abdominal Pain, Diarrhea